Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer

NCT03236974 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03236974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03236974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 5, 2017
Completion date
February 12, 2019
Enrollment
49 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal women with er+ her2- primary breast cancer